Clinical Trials

45 enrolled

Metastatic Gastric Adenocarcinoma

NCT06007937 2026-04-08

A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer

56 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Recurrence

NCT06445972 2026-04-02

MK-3475-06D

210 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT06996782 2026-03-30

ALTAIR

152 enrolled

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT06771622 2026-02-04

Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors

500 enrolled

Solid Cancer

NCT03008278 2026-02-03

Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery

51 enrolled 20 charts

Phase 1/2 Active not recruiting

Esophageal Neoplasms, Stomach Neoplasms

NCT03650764 2025-12-30

Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

43 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT03281369 2025-12-15

A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)

214 enrolled

Phase 1/2 Active not recruiting

Esophageal Neoplasms

NCT04145349 2025-12-08

CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor

30 enrolled 16 charts

Sarcoma

Sarcoma, Desmoplastic Small Round Cell Tumor

NCT05894824 2025-07-11

T-Dxd in Combination With Ramucirumab as HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

58 enrolled

Neoplasms, Stomach Neoplasms

NCT05062980 2025-02-20

Acclaim-2

Phase 1/2 Terminated

5 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04151563 2023-12-19

CheckMate 79X

Phase 1/2 Withdrawn

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT04145700 2023-09-13

CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma

Phase 1/2 Terminated

23 enrolled 15 charts

Sarcoma

Sarcoma, Sarcoma, Synovial

NCT03995017 2023-02-01

RiME

Phase 1/2 Unknown

34 enrolled

Adenocarcinoma Of Esophagus, Adenocarcinoma, Stomach Neoplasms

NCT04888663 2021-05-21

Study of Ramucirumab, Trastuzumab and Paclitaxel in Patients With HER2-positive Recurrent/Metastatic Gastric Cancer (HER-RAM Study)

Phase 1/2 Unknown

50 enrolled

Stomach Neoplasms

NCT02082210 2020-12-19

A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer

GastrointestinalGenitourinaryThoracic

97 enrolled 20 charts

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Liver Neoplasms

NCT03739801 2020-03-27

MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Phase 1/2 Withdrawn

Locally Advanced Unresectable Gastric Adenocarcinoma

NCT02999295 2019-08-21

A Phase 1/2 Study of Ramucirumab Plus Nivolumab in Participants With Gastric or GEJ Cancer

46 enrolled